Innoviva, Inc. Files 8-K on Financials

Ticker: INVA · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1080014

Innoviva, INC. 8-K Filing Summary
FieldDetail
CompanyInnoviva, INC. (INVA)
Form Type8-K
Filed DateAug 6, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

Related Tickers: INVA

TL;DR

INVA filed an 8-K on Aug 6 detailing financials. Check it out.

AI Summary

Innoviva, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1350 Old Bayshore Highway, Suite 400, Burlingame, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Innoviva's financial performance and operational status, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting on financial condition and results of operations, with no immediate or significant new risks indicated.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is August 6, 2025.

What is Innoviva, Inc.'s primary business address?

Innoviva, Inc.'s principal executive offices are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010.

Has Innoviva, Inc. operated under any previous names?

Yes, Innoviva, Inc. was formerly known as THERAVANCE INC and ADVANCED MEDICINE INC.

What is the SIC code for Innoviva, Inc.?

The Standard Industrial Classification (SIC) code for Innoviva, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Innoviva, Inc. (INVA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing